These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27073641)

  • 1. Impact of the
    Sun X; Yu WY; Ma WL; Huang LH; Yang GP
    Biomed Rep; 2016 Apr; 4(4):498-506. PubMed ID: 27073641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis.
    Liang R; Wang C; Zhao H; Huang J; Hu D; Sun Y
    Thromb Res; 2012 Jul; 130(1):38-44. PubMed ID: 22192158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis.
    Zhang J; Chen Z; Chen C
    Meta Gene; 2016 Sep; 9():197-209. PubMed ID: 27617219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Brandão LR; Ito S
    Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves.
    Lee KE; Chang BC; Kim HO; Yoon IK; Lee NR; Park HY; Gwak HS
    Ther Drug Monit; 2012 Jun; 34(3):275-82. PubMed ID: 22549502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study.
    Bejarano-Achache I; Levy L; Mlynarsky L; Bialer M; Muszkat M; Caraco Y
    Clin Ther; 2012 Apr; 34(4):811-23. PubMed ID: 22417713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of gamma-glutamyl carboxylase gene polymorphisms on warfarin dose requirement: a systematic review and meta-analysis.
    Sun Y; Wu Z; Li S; Qin X; Li T; Xie L; Deng Y; Chen J
    Thromb Res; 2015 Apr; 135(4):739-47. PubMed ID: 25681132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
    An SH; Chang BC; Lee KE; Gwak HS
    Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
    Zhuang W; Wu D; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of incorporating ABCB1 and CYP4F2 polymorphisms in a pharmacogenetics-guided warfarin dosing algorithm for the Brazilian population.
    Tavares LC; Duarte NE; Marcatto LR; Soares RAG; Krieger JE; Pereira AC; Santos PCJL
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1555-1566. PubMed ID: 30051215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.
    Wells PS; Majeed H; Kassem S; Langlois N; Gin B; Clermont J; Taljaard M
    Thromb Res; 2010 Jun; 125(6):e259-64. PubMed ID: 20421126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of polymorphisms of the GGCX gene on maintenance warfarin dose in Chinese populations: Systematic review and meta-analysis.
    Tian L; Zhang J; Xiao S; Huang J; Zhang Y; Shen J
    Meta Gene; 2015 Sep; 5():43-54. PubMed ID: 26106580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.
    Zhang J; Tian L; Huang J; Huang S; Chai T; Shen J
    Cardiovasc Ther; 2017 Feb; 35(1):26-32. PubMed ID: 27661060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP4F2 genetic variant alters required warfarin dose.
    Caldwell MD; Awad T; Johnson JA; Gage BF; Falkowski M; Gardina P; Hubbard J; Turpaz Y; Langaee TY; Eby C; King CR; Brower A; Schmelzer JR; Glurich I; Vidaillet HJ; Yale SH; Qi Zhang K; Berg RL; Burmester JK
    Blood; 2008 Apr; 111(8):4106-12. PubMed ID: 18250228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of VKORC1 gene polymorphism on warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.
    Zhang J; Tian L; Zhang Y; Shen J
    Thromb Res; 2015 Nov; 136(5):955-61. PubMed ID: 26433837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in Chinese valve replacement patients.
    Li JH; Ma GG; Zhu SQ; Yan H; Wu YB; Xu JJ
    J Cardiothorac Surg; 2012 Sep; 7():97. PubMed ID: 23013706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Genetic Variability in the
    Zhang JE; Klein K; Jorgensen AL; Francis B; Alfirevic A; Bourgeois S; Deloukas P; Zanger UM; Pirmohamed M
    Front Pharmacol; 2017; 8():323. PubMed ID: 28620303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.
    Borgiani P; Ciccacci C; Forte V; Sirianni E; Novelli L; Bramanti P; Novelli G
    Pharmacogenomics; 2009 Feb; 10(2):261-6. PubMed ID: 19207028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.